Chintu Patel - 15 Dec 2021 Form 4 Insider Report for Amneal Pharmaceuticals, Inc. (AMRX)

Role: Co-CEO, Director
Signature: /s/ Meredith Cook, Attorney-in-Fact
Issuer symbol: AMRX
Transactions as of: 15 Dec 2021
Transactions value $: $625,500
Form type: 4
Filing time: 17 Dec 2021, 15:15:14
Next filing: 03 Mar 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AMRX	Class A Common Stock	Purchase	$413K	+100K	+27.58%	$4.13	463K	15 Dec 2021	Direct	F1
transaction	AMRX	Class A Common Stock	Purchase	$213K	+50K	+10.81%	$4.25	513K	16 Dec 2021	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.06 to $4.18. The reporting person undertakes to provide Amneal Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or of the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.20 to $4.30. The reporting person undertakes to provide the Company, any security holder of the Company, or of the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Content

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.06 to $4.18. The reporting person undertakes to provide Amneal Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or of the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.20 to $4.30. The reporting person undertakes to provide the Company, any security holder of the Company, or of the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.